Uncategorized
November 1, 2023 / January 12, 2026 by necteromedical
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm. Nectero Therapeutics is initiating […]
Read more »